# US 2006/0188510 A1 · Antibody against secreted N-terminal peptide of GPC3 present in blood or C-terminal peptide of GPC3

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0188510 A1
- Document ID: US20060188510A1
- Status: Published application
- Kind: A1
- Application number: 11/414,676
- Filed: 2006-04-28
- Published: 2006-08-24
- Earliest claimed: 2002-09-04
- Assignees: Chugai Seiyaku Kabushiki Kaisha
- Inventors: Hiroyuki Aburatani; Yutaka Midorikawa; Kiyotaka Nakano; Iwao Ohizumi; Yukio Ito; Susumu Tokita
- Web page: https://patentgrep.com/patent/US20060188510A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/30: from tumour cells
- C07K 16/303: {Liver or Pancreas}
- C07K 17/00: Carrier-bound or immobilised peptides (carrier-bound or immobilised enzymes C12N11/00); Preparation thereof
- G01N 33/57585: {involving compounds identifiable in body fluids}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell disrupting agent and an anti-cancer agent comprising the same, which can disrupt cells, in particular cancer cells.

## Claims

### Claim 1

An antibody against an N-terminal peptide of GPC 3.

### Claim 2 (depends on 1)

The antibody claimed in claim 1 wherein the N-terminal peptide of GPC 3 is a secreted form of a peptide found in blood.

### Claim 3 (depends on 2)

The antibody claimed in claim 2 wherein the N-terminal peptide of GPC 3 is a peptide comprising amino acid residues 1-374 of GPC 3 or a peptide comprising amino acid residues 1-358 of GPC 3.

### Claim 4 (depends on 3)

The antibody claimed in claim 3 wherein the N-terminal peptide of GPC 3 is a peptide comprising amino acid residues 1-358 of GPC 3.

### Claim 5 (depends on 1)

The antibody claimed in claim 1 which is a monoclonal antibody.

### Claim 6 (depends on 1)

The antibody claimed in claim 1 which is immobilized to an insoluble support.

### Claim 7 (depends on 1)

The antibody claimed in claim 1 which is labeled with a labeling material.

### Claim at position 8

8-18. (canceled)
